Brind.
  1. INOVIO is submitting a Biologics License Application (BLA) to the FDA for INO-3107, a drug candidate being developed for the treatment of Recurrent Respiratory Papillomatosis (RRP).

INOVIO published trial data in The Laryngoscope, with Aaron Friedman serving as a principal investigator.

1 report, 1 independent Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

INOVIO published trial data in The Laryngoscope, with Aaron Friedman serving as a principal investigator.

Who's involved

What this event is mainly about
Aaron Friedman

Keep exploring

Part of

INOVIO is submitting a Biologics License Application (BLA) to the FDA for INO-3107, a drug candidate being developed for the treatment of Recurrent Respiratory Papillomatosis (RRP). All 1 developments

Coverage

Newest first; wire copies grouped
  • PR NewswireData Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) Retrospective trial showed Overall Response Rate (ORR) improved